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Background: Ticagrelor is an oral platelet P2Y12 receptor antagonist which is recommended for patients suffering
from myocardial infarction, both with and without persistent ST segment elevation. Morphine is the first choice drug in
pain alleviation in the same clinical subset. Recently a possible negative influence of morphine on the pharmacokinetics
and antiplatelet effects of P2Y12 receptor blockers has been postulated.
Methods/design: The IMPRESSION study is a phase IV, single center, randomized, double-blind, placebo-controlled
clinical trial that is designed to assess the influence of morphine on the pharmacokinetics and pharmacodynamics of
ticagrelor in patients with myocardial infarction. The study is planned to include up to 100 patients with myocardial
infarction who will be randomized into one of two arms in a 1:1 ratio. Subjects in the intervention arm prior to the
loading dose of ticagrelor (180 mg) will receive morphine (5 mg) intravenously, whereas patients in the control arm
will receive a placebo prior to the loading dose of ticagrelor (180 mg). The pharmacokinetics of ticagrelor and its active
metabolite (AR-C124910XX) will be assessed by liquid chromatography mass spectrometry. Platelet function testing in
each patient will be performed using up to four different methods (platelet vasodilator-stimulated phosphoprotein
assay, multiple electrode aggregometry, VerifyNow, and light transmission aggregometry).
Discussion: This study is expected to provide essential evidence-based data on the impact of morphine on the absorption
of ticagrelor in patients with myocardial infarction as well as to shed some light on the suspected connection between
morphine use and antiplatelet activity of ticagrelor in the same group of patients.
Trial registration: ClinicalTrials.gov identifier: NCT02217878 (14 August 2014).
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Platelet activation and aggregation play a pivotal role in
the pathophysiology of acute coronary syndromes (ACS),
including ST-segment elevation myocardial infarction
(STEMI) and non-ST-segment elevation myocardial in-
farction (NSTEMI). Dual antiplatelet therapy, consisting
of aspirin and one of the P2Y12 receptor antagonists,* Correspondence: piotr.adamski@wp.eu
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unless otherwise stated.constitutes the mainstay of ACS treatment. Achievement
of adequate and timely platelet inhibition is of vast im-
portance in the acute phase of myocardial infarction. Re-
sults of the PLATO trial have shown that therapy with
ticagrelor, a novel platelet P2Y12 receptor inhibitor,
compared with clopidogrel reduces not only the rate of
death from vascular causes, myocardial infarction, or
stroke, but also all-cause mortality, without concomitant
increase in the rate of overall major bleeding, in patients
with ACS [1,2]. The superiority of ticagrelor over clopido-
grel evidenced in the PLATO trial has been principallyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Inclusion and exclusion criteria for IMPRESSION
study
Inclusion Criteria
Provision of informed consent prior
to any study-specific procedures
Provision of informed consent for
angiography and PCI
Diagnosis of acute STEMI or acute
NSTEMI
Male or non-pregnant female,
aged 18 to 80 years old
Exclusion Criteria
Chest pain described by the patient
as unbearable or patient’s request
for analgesics
History of major surgery or severe
trauma (within 3 months)
Prior morphine administration
during the current STEMI or NSTEMI
Patients considered by the
investigator to be at risk of
bradycardic events
Treatment with ticlopidine,
clopidogrel, prasugrel, or ticagrelor





Hypersensitivity to ticagrelor Patient required dialysis
Current treatment with oral
anticoagulant or chronic therapy
with LMWH
History of asthma or severe
chronic obstructive pulmonary
disease
Active bleeding Manifest infection or
inflammatory state





History of coagulation disorders History of severe chronic heart
failure (NYHA class III or IV)




within 14 days and during study
treatment








Platelet count less than <100
x10^3/mcl
History of moderate or severe
hepatic impairment
Body weight below 50 kg
LMWH: low-molecular-weight heparin; NSTEMI: non-ST-segment elevation
myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous
coronary intervention; STEMI: ST-segment elevation myocardial infarction.
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codynamic features [2,3].
Based on the mentioned results, therapy with ticagre-
lor received class I B recommendation according to the
European Society of Cardiology (ESC) in interventionally
treated STEMI patients and in all moderate-to-high risk pa-
tients with ACS without persistent ST-segment elevation,
including NSTEMI patients, regardless of initial treatment
strategy [4,5]. Likewise, the American College of Cardiology
Foundation and American Heart Association (ACCF/AHA)
Task Force on Practice Guidelines recommend the use of
ticagrelor in these subsets of patients [6,7].The same ESC and ACCF/AHA guidelines recommend
the use of morphine as a treatment of choice for pain re-
lief in the clinical setting of myocardial infarction [4-6].
However, these recommendations, although strong, are
only based on expert consensus. Pain relief in patients
presenting with acute myocardial infarction (AMI) is sug-
gested to lead to decreased sympathetic activation, thus
preventing vasoconstriction and subsequent increase in
the workload of the heart. Additionally, apart from its an-
algesic effects, morphine also alleviates the work of breath-
ing and reduces anxiety [4,6]. On the other hand, despite its
favorable analgesic and sedative actions, morphine also ex-
erts adverse effects, which include hypotension, bradycardia,
respiratory depression, vomiting, and reduction of gastro-
intestinal motility. Importantly, both the safety and effi-
cacy of morphine have never been tested in randomized
trials in the ACS setting, while a large, retrospective ana-
lysis of the CRUSADE registry suggests that morphine ad-
ministration may be associated with increased mortality in
patients with non-ST-segment elevation ACS [8]. Some of
the previously listed side effects of morphine could affect
the intestinal absorption and thus the pharmacokinetics
(PK) and pharmacodynamics (PD) of orally administered
drugs which are concomitantly used with morphine. Note
that currently all commercially available P2Y12 blockers
are oral agents.
In concordance with those facts, it was observed that
morphine lags clopidogrel absorption, decreases plasma
levels of clopidogrel and its active metabolite, and delays
and diminishes antiplatelet effects of this thienopyridine, al-
though this was observed in a group of healthy volunteers
[9]. Moreover, Parodi et al. in their study comparing the
PD of ticagrelor and prasugrel in STEMI patients reported
that morphine administration may be associated with im-
paired antiplatelet effects of both investigated drugs [10].
However, a definitive evidence of a possible interaction
between morphine and the novel P2Y12 receptor antag-
onists may be obtained only in randomized studies. At
present, no PK and PD data regarding the concurrent
use of morphine and P2Y12 blockers in the ACS setting
are available. Therefore, evidence-based verification of
morphine’s influence on the PK and PD of ticagrelor and
its active metabolite (AR-C124910XX) could provide a
valuable insight into the knowledge regarding modern
ACS management.Methods/design
Study objectives
The primary objective of the Influence of Morphine on
Pharmacokinetics and Pharmacodynamics of Ticagrelor in
Patients with Acute Myocardial Infarction (IMPRESSION)
study is to test the hypothesis that intravenous administra-
tion of morphine prior to ticagrelor administration in
Figure 1 Trial schema for the IMPRESSION study. Legend: IV: intravenous; PCI: percutaneous coronary intervention.
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ticagrelor and its active metabolite.
The secondary objective of this study is to determine
whether intravenous administration of morphine prior
to ticagrelor administration in AMI patients attenuates
the antiplatelet effects of ticagrelor.
Additionally, a predefined subanalysis has been planned
to investigate which of the platelet reactivity assessment
methods utilized in the study best reflects concentration
of ticagrelor and its active metabolite.Study design and population
The IMPRESSION study is a phase IV, single center,
randomized, double-blind, placebo-controlled, PK and
PD clinical trial. The study population includes subjects
presenting with AMI, including both STEMI and
NSTEMI patients. After admission to the study center
(Cardiology Clinic, Dr. A. Jurasz University Hospital,
Bydgoszcz, Poland) and confirmation of the initial
STEMI or NSTEMI diagnosis, patients will receive orally
a 300-mg loading dose of plain aspirin and will be
screened for eligibility for the study. The inclusion andFigure 2 Blood sampling schedule for the IMPRESSION study.exclusion criteria are as listed in Table 1. Eligible patients
will be randomly assigned in a 1:1 ratio to one of two
study arms. The patients in the intervention arm will re-
ceive 5 mg of morphine intravenously (IV) followed by a
180-mg loading dose of ticagrelor, whereas patients in the
control arm will obtain 5 mg of a placebo IV followed by a
180-mg loading dose of ticagrelor (Figure 1). Subsequently
all patients will undergo a coronary angiography followed
by percutaneous coronary intervention (PCI), if necessary.
Blood samples for PK and PD assessment will be drawn at
eight predefined time points during the first 12 hours after
randomization, according to the blood sampling schedule
as presented in Figure 2. A telephone follow-up will be
conducted at 30 days post-randomization, which will con-
clude the subject’s participation in the study.
The study will be conducted in accordance with the princi-
ples contained in the Declaration of Helsinki, and the study
site received approval from the Local Ethics Committee to
conduct the study (Komisja Bioetyczna Uniwersytetu
Mikołaja Kopernika w Toruniu przy Collegium Medicum
im. Ludwika Rydygiera w Bydgoszczy; study approval ref-
erence number KB 111/2014). Each patient will provide a
written informed consent to participate in the study.
Figure 3 Pharmacodynamic assessment schedule for IMPRESSION study. Legend: GP IIb/IIIa: glycoprotein IIb/IIIa; LTA: light transmission
aggregometry; MEA: multiple electrode aggregometry.
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Blood plasma concentrations of ticagrelor and AR-
C124910XX will be evaluated using liquid chromatog-
raphy mass spectrometry in samples obtained in eight
predefined time points (Figure 2).
Pharmacodynamics
Assessment of ticagrelor’s antiplatelet effects will be per-
formed using up to four different methods (Figure 3). A
platelet vasodilator-stimulated phosphoprotein (VASP)
assay will be applied to all study participants at all pre-
defined time points (Figure 2). Multiple electrode aggre-
gometry (MEA) will be used at all predefined time
points for all study participants with the exception of
those treated with glycoprotein IIb/IIIa (GP IIb/IIIa) re-
ceptor inhibitors. VerifyNow and light transmission
aggregometry (LTA) will be applied for at least 30% of
all enrolled study participants at all predefined timeTable 2 Baseline characteristics
STEMI (n = 22) NSTEMI (n = 11) Total (n = 33)
Age in years, median 62.6 62.4 62.5
Age≥ 70 9 (40.9%) 2 (18.2%) 9 (27.3%)
Female 5 (22.7%) 2 (18.2%) 7 (21.2%)
Hypertension 7 (31.8%) 8 (72.7%) 15 (45.5%)
Diabetes mellitus 5 (22.7%) 2 (18.2%) 7 (21.2%)
Dyslipidemia 19 (86.4%) 8 (72.7%) 27 (81.8%)
Current smoker 9 (40.9%) 6 (54.5%) 15 (45.5%)
Prior MI 1 (4.5%) 3 (27.3%) 4 (12.2%)
Prior PCI 1 (4.5%) 5 (45.5%) 6 (18.2%)
Prior CABG 0 0 0
BMI in kg/m2 28.4 27.4 28.1
BMI: body mass index; CABG: coronary artery bypass surgery; MI:
myocardial infarction.points. Measurements with VerifyNow and LTA will not
be performed in patients treated with GP IIb/IIIa recep-
tor inhibitors. Details regarding methods to be used for
the assessment of platelet reactivity were previously de-
scribed [11-14].
Treatment protocol and concomitant medications
During their participation in the study, all patients will
be treated according to the current ESC guidelines. Ad-
ministration of GP IIb/IIIa receptor inhibitors will be re-
stricted to bailout situations. Interventional cardiologists
will be encouraged to use manual thrombectomy in case
of visible thrombus. The choice of the access of the cor-
onary invasive procedure (radial or femoral) and the type
of implanted stent (drug-eluting stent [DES] or bare
metal stent [BMS]) will be at the discretion of the oper-
ator, although high rates of radial access and DES im-
plantation are expected to occur. From the loading dose
of ticagrelor until completion of the study, all patients
will receive maintenance doses of ticagrelor (90 mg)
twice daily. In addition, standard therapy will include as-
pirin (75 to 100 mg daily), beta blockers, statins, and
angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers, if not contraindicated.
Study endpoints
The primary endpoint of this trial is the area under the
plasma concentration-time curve (AUC(0–12)) for ticagrelor
for the first 12 hours after the loading dose of ticagrelor.
Secondary endpoints include AUC(0–12) for AR-C124910XX,
maximum concentration (Cmax) of ticagrelor and AR-C1
24910XX, time to Cmax for ticagrelor and AR-C124910XX,
platelet reactivity index (PRI) assessed by VASP assay, area
under the aggregation curve assessed by MEA, P2Y12 re-
action units (PRU) assessed by VerifyNow, and ADP-
induced platelet aggregation assessed by LTA.
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The following safety endpoints will be recorded: definite
stent thrombosis according to the Academic Research
Consortium criteria, major and minor, recurrent myocar-
dial infarction according to the Third Universal Definition
of Myocardial Infarction, all-cause death, stroke, and tran-
sient ischemic attack (TIA) according to definitions used
in the PLATO trial, minor and major bleedings according
to the BARC, PLATO, and TIMI criteria, dyspnea adverse
events according to criteria used in the PLATO trial, bra-
dyarrhythmic events according to criteria used in the
PLATO trial.
Statistics
Since there is no reference study examining the PK of
ticagrelor in patients presenting with STEMI or
NSTEMI, we decided to perform an internal pilot study
of approximately 30 patients (15 patients for each arm)
to estimate the final sample size. The means and stand-
ard deviations of AUC(0–12) for ticagrelor in the first 33
patients assessed for patients who received morphine
and for patients who received the placebo were 6,917 ±
4,920 and 10,379 ± 5,996 ng · h/ml, respectively. Based on
these results and assuming a two-sided alpha value of 0.05,
we calculated, using the t-test for independent variables,
that enrollment of 68 patients would provide an 80%
power to demonstrate a significant difference in AUC(0–12)
for ticagrelor between patients who received morphine
prior to a loading dose of ticagrelor and those who received
the placebo prior to the ticagrelor loading dose.
Continuous variables will be compared between both
study arms by the Student’s t-test or the Mann–Whitney
U test, depending on the presence or absence of the nor-
mal distribution (as assessed by the Kolmogorov-Smirnov
test). Proportions will be compared by the Fisher exact
test or chi-square test when appropriate. Pharmacokinetic
calculations will be performed using a dedicated software.
Discussion
The IMPRESSION study is a phase IV, single center,
randomized, double-blind, placebo-controlled clinical
trial that assesses the influence of morphine on the PK
and antiplatelet effects of ticagrelor in patients with
myocardial infarction. This trial will provide important in-
formation regarding the impact of morphine, the analgesic
which is most commonly used in patients with AMI, on
the absorption of ticagrelor in subjects presenting with
STEMI and NSTEMI. Furthermore, the study could spe-
cify the suspected connection between alterations in tica-
grelor absorption and modification of its antiplatelet
activity. A disclosure of such drug-drug interaction in
AMI patients could supply a significant evidence-based
data source regarding concurrent use of ticagrelor and
morphine in STEMI and NSTEMI treatment.Trial status
The first patient was enrolled in August 2014. Initially
the IMPRESSION study was planned to include STEMI
patients only. However, on 9 September 2014, after the
approval of the Local Ethics Committee, the trial popu-
lation was expanded to include subjects with NSTEMI
as well. By 8 January 2015, 33% of planned patients were
successfully included in the study. The baseline charac-
teristics of the enrolled patients are presented in Table 2.
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